Home » Stocks » CALA

Calithera Biosciences, Inc. (CALA)

Stock Price: $2.92 USD -0.06 (-2.01%)
Updated Feb 25, 2021 3:58 PM EST - Market closed
After-hours: $2.94 +0.02 (0.69%) Feb 25, 4:40 PM
Market Cap 211.68M
Revenue (ttm) n/a
Net Income (ttm) -89.30M
Shares Out 70.56M
EPS (ttm) -1.38
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 25
Last Price $2.92
Previous Close $2.98
Change ($) -0.06
Change (%) -2.01%
Day's Open 3.00
Day's Range 2.85 - 3.01
Day's Volume 1,018,219
52-Week Range 2.46 - 8.18

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 1 month ago

Investors need to pay close attention to Calithera Biosciences (CALA) stock based on the movements in the options market lately.

GlobeNewsWire - 1 month ago

SOUTH SAN FRANCISCO, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel sm...

Zacks Investment Research - 1 month ago

Calithera (CALA) tanks as CANTATA study on its lead pipeline candidate, telaglenastat, did not achieve its primary goal for RCC.

GlobeNewsWire - 1 month ago

SOUTH SAN FRANCISCO, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel sm...

Benzinga - 1 month ago

Calithera Biosciences (NASDAQ: CALA) shares are trading lower after the company announced that its CANTATA study of Telaglenastat in Renal Cell Carcinoma did not achieve its primary endpoint. ...

Other stocks mentioned: BNGO
The Motley Fool - 1 month ago

The company reported negative results from a clinical trial.

GlobeNewsWire - 1 month ago

-- Company will continue to advance telaglenastat KEAPSAKE trial in non-small cell lung cancer, arginase inhibitor CB-280 trial in cystic fibrosis and emerging pipeline

GlobeNewsWire - 1 month ago

SOUTH SAN FRANCISCO, Calif., Dec. 31, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel sm...

Zacks Investment Research - 2 months ago

Investors need to pay close attention to Calithera (CALA) stock based on the movements in the options market lately.

GlobeNewsWire - 2 months ago

SOUTH SAN FRANCISCO, Calif., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel sm...

Seeking Alpha - 3 months ago

Calithera has an important near-term catalyst that could launch the company into a significant commercialization opportunity by mid-year 2021. The company also is running a triplet therapy tri...

GlobeNewsWire - 3 months ago

SOUTH SAN FRANCISCO, Calif., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel sm...

GlobeNewsWire - 3 months ago

IL4I1 inhibitor shows immune-mediated anti-tumor activity IL4I1 inhibitor shows immune-mediated anti-tumor activity

Seeking Alpha - 3 months ago

Calithera Biosciences' (CALA) CEO Susan Molineaux on Q3 2020 Results - Earnings Call Transcript

GlobeNewsWire - 3 months ago

--Calithera to Provide Corporate Update via Conference Call and Webcast at2:00 p.m. PT on November 5, 2020-- SOUTH SAN FRANCISCO, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Calithera Bioscience...

GlobeNewsWire - 3 months ago

Combination will be evaluated in patients with pancreatic ductal adenocarcinoma whose tumors have KRAS and CDKN2A mutations Combination will be evaluated in patients with pancreatic ductal ade...

GlobeNewsWire - 3 months ago

SOUTH SAN FRANCISCO, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel sm...

GlobeNewsWire - 3 months ago

SOUTH SAN FRANCISCO, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel sm...

GlobeNewsWire - 4 months ago

SOUTH SAN FRANCISCO, Calif., Oct. 07, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel sm...

GlobeNewsWire - 4 months ago

SOUTH SAN FRANCISCO, Calif., Oct. 02, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel sm...

GlobeNewsWire - 5 months ago

- Study will evaluate safety and efficacy of glutaminase inhibition in combination with standard - of - care treatment in front-line setting among  patients with non-small cell lung cancer...

GlobeNewsWire - 5 months ago

SOUTH SAN FRANCISCO, Calif., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel...

Seeking Alpha - 6 months ago

Calithera Biosciences, Inc. (CALA) CEO Susan Molineaux on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 6 months ago

--Calithera to Provide Corporate Update via Conference Call and Webcast at 2:00 p.m. PT on August 10, 2020-- SOUTH SAN FRANCISCO, Calif., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Calithera Bioscien...

GlobeNewsWire - 6 months ago

SOUTH SAN FRANCISCO, Calif., July 28, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel ...

GlobeNewsWire - 7 months ago

Former Portola Pharmaceuticals President and Chief Executive Officer Brings Extensive Executive Leadership and Commercial Oncology Experience Former Portola Pharmaceuticals President and Chief...

GlobeNewsWire - 7 months ago

SOUTH SAN FRANCISCO, July 13, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small mo...

GlobeNewsWire - 7 months ago

SOUTH SAN FRANCISCO, Calif., July 02, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel ...

GlobeNewsWire - 8 months ago

SOUTH SAN FRANCISCO, Calif., June 02, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel ...

GlobeNewsWire - 8 months ago

SOUTH SAN FRANCISCO, Calif., May 29, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel s...

Zacks Investment Research - 9 months ago

Is (CALA) Outperforming Other Medical Stocks This Year?

Zacks Investment Research - 9 months ago

Calithera Biosciences (CALA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Zacks Investment Research - 9 months ago

Calithera (CALA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Seeking Alpha - 9 months ago

Calithera Biosciences, Inc. (CALA) CEO Susan Molineaux on Q1 2020 Results - Earnings Call Transcript

GlobeNewsWire - 9 months ago

-- KEAPSAKE is a Phase 2 randomized trial exploring telaglenastat with standard of care in first-line treatment of patients with lung cancer with KEAP1/NRF2 mutations -- KEAPSAKE is a Phase 2 ...

GlobeNewsWire - 10 months ago

SOUTH SAN FRANCISCO, Calif., April 20, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel...

GlobeNewsWire - 10 months ago

SOUTH SAN FRANCISCO, Calif., April 16, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel...

GlobeNewsWire - 10 months ago

SOUTH SAN FRANCISCO, Calif., April 15, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel...

Zacks Investment Research - 10 months ago

Calithera (CALA) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

GlobeNewsWire - 10 months ago

SOUTH SAN FRANCISCO, April 14, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small-m...

Seeking Alpha - 11 months ago

Calithera Biosciences, Inc. (CALA) CEO Susan Molineaux on Q4 2019 Results - Earnings Call Transcript

GlobeNewsWire - 1 year ago

SOUTH SAN FRANCISCO, Calif., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel ...

GlobeNewsWire - 1 year ago

SOUTH SAN FRANCISCO, Calif., Jan. 03, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel ...

GlobeNewsWire - 1 year ago

SOUTH SAN FRANCISCO, Calif., Dec. 05, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel ...

Seeking Alpha - 1 year ago

Calithera Biosciences, Inc. (CALA) CEO Susan Molineaux on Q3 2019 Results - Earnings Call Transcript

GlobeNewsWire - 1 year ago

- First presentation of preclinical data for newly-announced IL4I1 immuno-oncology program

Zacks Investment Research - 1 year ago

Calithera (CALA) completes patient enrollment in a phase II study evaluating a combination regimen of its lead candidate, telaglenastat, in patients with advanced kidney cancer.

GlobeNewsWire - 1 year ago

SOUTH SAN FRANCISCO, Calif., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel...

GlobeNewsWire - 1 year ago

Responses observed in patients with microsatellite stable (MSS) colorectal cancer, a disease not historically sensitive to checkpoint inhibition Responses observed in patients with microsatell...

GlobeNewsWire - 1 year ago

SOUTH SAN FRANCISCO, Calif., Sept. 28, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel...

About CALA

Calithera Biosciences, a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase II clinical trial to treat solid tumors. The company also offers INCB001158, an oral inhibitor of arginase that is in Phase I/II clinical trial for the treatment of hematology and oncology. The company is also developin... [Read more...]

Industry
Biotechnology
IPO Date
Oct 2, 2014
CEO
Susan Molineaux
Employees
90
Stock Exchange
NASDAQ
Ticker Symbol
CALA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for CALA stock is "Buy." The 12-month stock price forecast is 5.00, which is an increase of 71.23% from the latest price.

Price Target
$5.00
(71.23% upside)
Analyst Consensus: Buy